Establishing Steady State Before Sampling

Why Steady State Must Be Established, Not Assumed

In a multiple-dose study, the planned sampling time is meaningful only if the dosing history supports the intended interpretation. A concentration measured after several doses may still reflect ongoing drug accumulation toward a repeating profile. Conversely, the number of doses is not itself evidence that this profile has been reached: the time elapsed depends on the dosing interval, and the rate of approach depends on the drug’s disposition and sometimes its absorption.

Steady state is especially relevant when a study is intended to characterize concentrations during a stable repeated-dose regimen. The practical question before sampling is not whether the participant has taken a prescribed number of doses, but whether a stable, repeatable concentration-time pattern is plausible under the actual regimen. That requires checking both the dosing history and the concentration data, when available.

What the Dosing History Can Tell You

For a drug with first-order elimination, the half-life \(t_{1/2}\) is the time required for the relevant concentration component to fall by one half. If a single exponential component is followed for \(T\) hours, its remaining fraction is \(2^{-T/t_{1/2}}\). This gives a useful time-scale check: after four half-lives, 6.25% of that component remains; after five, 3.125% remains.

These percentages help explain the common planning rule that approximately four to five half-lives may be needed for a drug to approach steady state. They are not universal acceptance limits. Whether a remaining difference of a few percent is adequate depends on the study purpose, measurement precision, the relevant pharmacokinetic component, and any prespecified criterion. A fixed dose count cannot substitute for elapsed time: ten doses every 24 hours span a different duration from ten doses every 8 hours.

A half-life calculation also needs the correct clock. Record the time of the first dose, each subsequent dose, any missed or delayed doses, and the exact sample time relative to the most recent dose. For a sample just before a scheduled dose, count the elapsed intervals from the first dose carefully; do not confuse the time of the last administered dose with the time of the predose sample.

A Model-Based Justification for the Time Check

The half-life calculation can be connected directly to repeated dosing in a simple model. Assume instantaneous equal doses, one-compartment disposition, linear pharmacokinetics, and first-order elimination. Let \(\Delta C\) be the concentration increase caused by one dose, and let \(q=2^{-\tau/t_{1/2}}\) be the fraction remaining after one dosing interval of length \(\tau\). Write \(C_n^-\) for the concentration just before dose \(n\), after \(n-1\) doses. Between doses, concentration is multiplied by \(q\), and a dose adds \(\Delta C\).

At steady state, the predose concentration \(C_{\infty}^-\) repeats each interval, so it satisfies \(C_{\infty}^-=q(C_{\infty}^-+\Delta C)\). Define the deficit after \(n-1\) doses as \(e_n=C_{\infty}^- - C_n^-\). Subtracting the current-profile recurrence from the steady-state equation gives \(e_{n+1}=q e_n\). Starting with no drug, \(C_1^-=0\), so \(e_1=C_{\infty}^-\). Repeated substitution therefore gives the relative deficit after \(n\) complete dosing intervals as \(q^n\), or \(2^{-n\tau/t_{1/2}}\). This derivation explains why elapsed time in half-lives, rather than dose count alone, matters.

The derivation is exact only for the stated simplified model. With oral dosing, drug input is spread over time; with multiple distribution phases, the profile may contain more than one exponential component. In such cases, the one-component calculation is a planning approximation, not a substitute for a suitable pharmacokinetic model or observed profiles.

Using Concentration Profiles as Evidence

When serial concentrations are available, compare observations taken at the same phase of successive dosing intervals. For example, predose concentrations should be compared with predose concentrations, rather than with samples collected at varying times after a dose. A rising sequence of consistently timed predose values is evidence that the profile is still changing. Similar values over successive intervals support an approximate plateau, although measurement variability can obscure small changes.

A plateau is most informative when the dose, dose interval, formulation, meal conditions where relevant, and sampling times have been consistent. Also check that recorded administration times match the protocol. If one sample is later after the dose than another, a concentration difference could reflect within-interval decline rather than movement toward or away from steady state.

Assumptions, Diagnostics, and Failure Modes

A time-since-first-dose calculation is most defensible when the regimen is stable and the relevant pharmacokinetics are approximately linear and time-invariant. In particular, the same dose is given at regular intervals, adherence is adequate, and clearance and other disposition characteristics do not change materially during the period. Under those conditions, a stable regimen can produce a repeating profile.

Before concluding that steady state is plausible, check the following:

• Dose history: verify dose amounts, administration times, missed or delayed doses, and any recent regimen changes.
• Elapsed time: calculate time from the first relevant dose to sampling and compare it with an appropriate half-life estimate.
• Sampling phase: compare concentrations collected at comparable times within the dosing interval.
• Profile pattern: look for a continuing trend across comparable samples, while considering assay and biological variability.
• Model suitability: question a simple half-life estimate when absorption is prolonged, more than one disposition phase matters, or pharmacokinetics may be nonlinear or time-varying.

A long terminal half-life may be a poor guide if the observed sampling window is governed by a different, slower input process or by multiple phases. Conversely, if clearance changes with time or concentration, the assumption of a fixed half-life may fail. In those circumstances, use relevant concentration data and a pharmacokinetic model that represents the process, rather than treating a rule of thumb as proof.

Choosing the Evidence and Recognizing Its Limits

Three approaches contribute different kinds of evidence. A dosing-history check establishes what happened and whether sampling followed the intended regimen, but it cannot alone show that concentrations have stabilized. A half-life-based check estimates how much time the drug may need to approach a repeating profile, but depends on the relevance of the half-life and model assumptions. A serial-profile check observes whether comparable concentrations are still changing, but is limited by the number, timing, and precision of samples.

These approaches are complementary, not interchangeable. A study can use a pharmacokinetic model to predict a suitable duration before sampling, then verify the dose history and review appropriately timed concentrations. If observed values continue to trend, a nominally adequate dose count or planned duration should not override that evidence. The study’s operational definition of adequate stability should be set in advance and suited to its objective.

Steady state is also not synonymous with a flat concentration curve. A profile can rise and fall substantially within every interval while repeating almost exactly from one interval to the next. Nor does a handful of similar measurements establish that every part of the concentration-time curve repeats; the conclusion is limited to the regimen, time points, and precision actually assessed.

Common Mistakes

• Counting doses instead of calculating elapsed time. The correction is to use dose times and the planned sample time, then compare elapsed time with the relevant half-life.
• Misplacing a predose sample. A dose at 84 hours followed by a 12-hour interval means the next predose time is 96 hours, not 84 hours. Write the full dose schedule before calculating.
• Treating four or five half-lives as a guarantee. This is a useful approximation for a simple exponential process, not a universal proof or acceptance criterion.
• Calling a profile “steady” because it is flat within one interval. Steady state means the profile repeats between intervals; it need not be constant within an interval.
• Comparing concentrations collected at different postdose times. Use comparable sampling phases, or account for timing differences with an appropriate model.